AI Assistant
Blog
Pricing
Log In
Sign Up
38 Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: final results
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
